Carfilzomib

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Multiple Myeloma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (2)
JP
  • Kyprolis (Ono): relapsed or refractory multiple myeloma
Product first approved 2016ono-pharma.com
EU
  • Kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Product first approved 2015EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (25)
Multiple Myeloma
NCT07222761 · Regeneron Pharmaceuticals
2026-01-02 – 2034-08-23 · Relapsed and/or Refractory Multiple Myeloma (RRMM)
What this study did
NCT01863550 · ECOG-ACRIN Cancer Research Group
2013-12-06 – 2034-02-05 · Plasma Cell Myeloma
What this study did
NCT04483739 · European Myeloma Network B.V.
2020-09-25 – 2032-12-31 · Multiple Myeloma
What this study did
NCT06615479 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
2025-03-12 – 2032-06-22 · Relapsed or Refractory Multiple Myeloma (RRMM)
What this study did
NCT05572515 · Janssen Research & Development, LLC
2023-03-29 – 2031-08-31 · Multiple Myeloma
What this study did
NCT03742297 · PETHEMA Foundation
2018-10-22 – 2031-01 · Newly Diagnosed Multiple Myeloma
What this study did
NCT03948035 · Wuerzburg University Hospital
2018-08-28 – 2029-08 · Newly Diagnosed Multiple Myeloma
What this study did
NCT05552976 · Bristol-Myers Squibb
2023-01-10 – 2029-07-25 · Relapsed or Refractory Multiple Myeloma
What this study did
A Study of Daratumumabactive not recruiting
NCT05438043 · Janssen Research & Development, LLC
2022-12-15 – 2029-01-31 · Multiple Myeloma
What this study did
NCT02659293 · University of Chicago
2016-04-26 – 2027-11 · Multiple Myeloma
What this study did
NCT04096066 · Fondazione EMN Italy Onlus
2019-07-01 – 2027-09-01 · Multiple Myeloma, New Diagnosis Tumor
What this study did
NCT03729804 · University of Chicago
2019-05-07 – 2026-12-28 · Multiple Myeloma
What this study did
NCT03651128 · Celgene
2019-04-16 – 2026-04-13 · Multiple Myeloma
What this study did
NCT04288765 · Grupo Cooperativo de Hemopatías Malignas
2020-03-01 – 2025-02-28 · Multiple Myeloma
What this study did
NCT03859427 · Amgen
2019-05-08 – 2023-03-31 · Relapsed or Refractory Multiple Myeloma
What this study did
NCT01554852 · University of Leeds
2010-05 – 2022-12 · Multiple Myeloma
What this study did
NCT03029234 · Amgen
2017-03-31 – 2021-06-04 · Relapsed and Refractory Multiple Myeloma
What this study did
NCT01818752 · Amgen
2013-07-08 – 2016-11-04 · Multiple Myeloma
What this study did
Phase 2/3 (2)
Multiple Myeloma
NCT04513639 · Oslo University Hospital
2020-08-27 – 2032-06-01 · Multiple Myeloma
What this study did
NCT06879379 · Peking University People's Hospital
2025-03 – 2029-03 · Multiple Myeloma, Newly Diagnosed
What this study did
Phase 2 (91)
Multiple Myeloma
NCT04933539 · National Cancer Institute (NCI)
2022-10-31 – 2032-10-31 · Multiple Myeloma
What this study did
NCT04883242 · University of Washington
2021-07-29 – 2031-12-31 · Recurrent Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT03289299 · International Myeloma Foundation
2018-05-25 – 2031-11-15 · Smoldering Multiple Myeloma
What this study did
NCT05896228 · Benjamin T Diamond, MD
2024-02-20 – 2031-03-01 · Refractory Multiple Myeloma, Relapsed Multiple Myeloma
What this study did
NCT06627751 · Roswell Park Cancer Institute
2025-05-01 – 2030-05-01 · Extramedullary Disease in Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT02315716 · University College, London
2015-06-16 – 2029-11 · Multiple Myeloma
What this study did
NCT04850599 · OHSU Knight Cancer Institute
2022-06-14 – 2029-02-21 · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT07348393 · Assistance Publique - Hôpitaux de Paris
2026-02 – 2029-02 · Relapsed or Refractory Multiple Myeloma (RRMM)
What this study did
NCT05669989 · Sanofi
2023-04-05 – 2028-11-30 · Plasma Cell Myeloma
What this study did
NCT03004287 · University of Arkansas
2017-07-01 – 2028-10 · Multiple Myeloma
What this study did
NCT05497804 · Mayo Clinic
2022-09-22 – 2028-09-04 · ISS Stage III Plasma Cell Myeloma, Multiple Myeloma
What this study did
NCT05789303 · University of Chicago
2023-05-30 – 2028-07-01 · Multiple Myeloma, Relapse Multiple Myeloma
What this study did
NCT05704049 · Sanofi
2023-04-05 – 2028-05-12 · Relapsed/Refractory Multiple Myeloma
What this study did
NCT04176718 · Andrew Yee, MD
2020-05-18 – 2028-05 · Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse, Relapse
What this study did
NCT03606577 · Nantes University Hospital
2019-07-30 – 2028-04-18 · Multiple Myeloma
What this study did
NCT04661137 · Hackensack Meridian Health
2021-03-16 – 2028-02 · Multiple Myeloma
What this study did
NCT03815279 · Landspitali University Hospital
2019-06-24 – 2028-01 · Multiple Myeloma, Smoldering Multiple Myeloma
What this study did
NCT04756401 · Academic and Community Cancer Research United
2022-12-08 – 2027-12-30 · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT06140966 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2023-10-20 – 2027-10-20 · Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma
What this study did
NCT04113018 · Wake Forest University Health Sciences
2020-01-10 – 2027-10 · Multiple Myeloma
What this study did
NCT03290950 · Memorial Sloan Kettering Cancer Center
2017-09-25 – 2027-09 · Multiple Myeloma
What this study did
NCT06356571 · Sanofi
2025-03-17 – 2027-07-15 · Plasma Cell Myeloma Refractory
What this study did
NCT03556332 · Memorial Sloan Kettering Cancer Center
2018-07-02 – 2027-07 · Multiple Myeloma
What this study did
NCT05909826 · Dong-A University Hospital
2023-07-01 – 2027-06-30 · Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
What this study did
NCT02415413 · PETHEMA Foundation
2015-05 – 2027-06 · Smoldering Multiple Myeloma
What this study did
NCT02899052 · AbbVie
2017-01-19 – 2027-06 · Multiple Myeloma
What this study did
NCT04268498 · University of Miami
2020-02-11 – 2027-02-01 · Multiple Myeloma
What this study did
KRDI in Transplant-Eligible MMactive not recruiting
NCT04430894 · Massachusetts General Hospital
2020-07-10 – 2026-12-30 · Multiple Myeloma
What this study did
NCT04925193 · University of Colorado, Denver
2021-11-18 – 2026-11 · Multiple Myeloma in Relapse
What this study did
NCT03104842 · Universitätsklinikum Hamburg-Eppendorf
2017-08-15 – 2026-09 · Multiple Myeloma
What this study did
NCT03756896 · Emory University
2019-01-25 – 2026-06-30 · Plasma Cell Myeloma
What this study did
NCT03500445 · University of Chicago
2019-02-13 – 2026-06 · Myeloma, Multiple Myeloma
What this study did
NCT04287855 · Poitiers University Hospital
2020-08-28 – 2026-04-15 · Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
What this study did
NCT01816971 · University of Chicago
2013-01 – 2026-03-30 · Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
What this study did
NCT01559935 · Weill Medical College of Cornell University
2012-04-19 – 2026-03-19 · Multiple Myeloma
What this study did
NCT02969837 · University of Chicago
2017-07-10 – 2025-12-01 · Multiple Myeloma
What this study did
NCT01572480 · National Cancer Institute (NCI)
2012-05-29 – 2025-02-28 · Multiple Myeloma
What this study did
NCT03336073 · PETHEMA Foundation
2017-12-18 – 2024-12 · Multiple Myeloma
What this study did
NCT04191616 · Amgen
2020-08-06 – 2024-10-01 · Relapsed or Refractory Multiple Myeloma
What this study did
NCT04892446 · Gilead Sciences
2021-11-09 – 2024-04-25 · Multiple Myeloma
What this study did
NCT02891811 · Arbeitsgemeinschaft medikamentoese Tumortherapie
2017-03-10 – 2024-03-28 · Multiple Myeloma
What this study did
NCT03155100 · Raija Silvennoinen
2017-08-07 – 2023-08-31 · Multiple Myeloma in Relapse
What this study did
NCT01346787 · European Myeloma Network B.V.
2011-07 – 2023-05-31 · Multiple Myeloma
What this study did
NCT03871829 · Janssen Research & Development, LLC
2019-05-31 – 2023-01-10 · Multiple Myeloma
What this study did
NCT03140943 · National University Hospital, Singapore
2017-09-13 – 2022-06-01 · Relapsed and/or Refractory Multiple Myeloma
What this study did
NCT02597062 · Canadian Cancer Trials Group
2016-07-05 – 2022-02-01 · Multiple Myeloma
What this study did
Phase 1/2 (48)
Multiple Myeloma
NCT04822337 · Wake Forest University Health Sciences
2021-05-19 – 2032-11 · Multiple Myeloma
What this study did
NCT07479979 · Natalie Callander
2026-05-21 – 2029-07 · Relapse Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT05434689 · University of Alabama at Birmingham
2023-01-18 – 2028-08 · Multiple Myeloma
What this study did
NCT02773030 · Celgene
2016-10-14 – 2028-07-28 · Multiple Myeloma
What this study did
NCT05060627 · PETHEMA Foundation
2021-12-20 – 2028-05-30 · Relapsed Multiple Myeloma
What this study did
NCT04764942 · Mayo Clinic
2021-05-06 – 2027-12-17 · Recurrent Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT01297764 · Hackensack Meridian Health
2011-04 – 2027-06 · Multiple Myeloma
What this study did
NCT02343042 · Karyopharm Therapeutics Inc
2015-10 – 2027-04 · Multiple Myeloma
What this study did
NCT05199311 · Hackensack Meridian Health
2022-05-13 – 2027-03 · Multiple Myeloma
What this study did
NCT01665794 · University of Chicago
2012-08-13 – 2025-11-14 · Multiple Myeloma
What this study did
NCT06055075 · Hoffmann-La Roche
2023-12-08 – 2025-07-08 · Relapsed or Refractory Multiple Myeloma
What this study did
NCT02937571 · Memorial Sloan Kettering Cancer Center
2016-10 – 2024-10-08 · Multiple Myeloma
What this study did
NCT01857115 · European Myeloma Network B.V.
2013-04 – 2024-09-01 · Multiple Myeloma
What this study did
NCT03773107 · Wake Forest University Health Sciences
2019-01-03 – 2024-02-21 · Multiple Myeloma
What this study did
NCT03795597 · Loyola University
2019-05-22 – 2023-11-01 · Multiple Myeloma
What this study did
NCT02002598 · Suzanne Lentzsch, MD
2013-11 – 2023-07-01 · Multiple Myeloma
What this study did
NCT02204241 · European Myeloma Network B.V.
2014-06 – 2023-04 · Multiple Myeloma
What this study did
NCT02056756 · Stichting European Myeloma Network
2014-04 – 2023-01-30 · Multiple Myeloma
What this study did
NCT02185820 · European Myeloma Network B.V.
2014-06 – 2023-01 · Multiple Myeloma
What this study did
NCT03201250 · University of Nebraska
2018-02-21 – 2021-04-12 · Multiple Myeloma, Refractory Multiple Myeloma, Relapsed/Refractory Multiple Myeloma
What this study did
NCT02802163 · H. Lee Moffitt Cancer Center and Research Institute
2017-06 – 2020-12 · Multiple Myeloma
What this study did
NCT01496118 · SCRI Development Innovations, LLC
2011-12 – 2020-12 · Multiple Myeloma
What this study did
NCT01464034 · Criterium, Inc.
2011-11 – 2020-07 · Multiple Myeloma
What this study did
NCT01842308 · Mayo Clinic
2013-06-04 – 2019-10-28 · DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT01962792 · Pharmacyclics LLC.
2013-12 – 2019-03 · Multiple Myeloma
What this study did
NCT01792102 · Oncotherapeutics
2013-04 – 2018-12 · Multiple Myeloma
What this study did
NCT01677858 · Amgen
2012-07-04 – 2018-10-31 · Multiple Myeloma
What this study did
NCT01246063 · Washington University School of Medicine
2012-05-14 – 2018-03-23 · Multiple Myeloma
What this study did
NCT01690143 · University of Alabama at Birmingham
2012-05 – 2017-11-01 · Multiple Myeloma
What this study did
NCT01057225 · Mayo Clinic
2010-03 – 2017-09-05 · Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
What this study did
NCT01365559 · Oncotherapeutics
2011-05-02 – 2016-03-01 · Multiple Myeloma
What this study did
NCT01029054 · University of Michigan Rogel Cancer Center
2009-09 – 2015-07 · Multiple Myeloma
What this study did
NCT01658904 · National Cancer Institute (NCI)
2012-07 – 2014-04 · Multiple Myeloma, Leukemia, Plasma Cell
What this study did
NCT01279694 · Nantes University Hospital
2010-10 – 2014-02 · Myeloma
What this study did
Other / comorbidity
NCT05017545 · National Institute of Allergy and Infectious Diseases (NIAID)
2021-12-28 – 2027-04 · Highly Sensitized Prospective Kidney Transplant Recipients
What this study did
NCT02073097 · Case Comprehensive Cancer Center
2015-01-28 – 2023-06-29 · Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma
What this study did
NCT02341014 · Memorial Sloan Kettering Cancer Center
2015-01-02 – 2023-01-11 · T-cell Lymphomas, Relapsed or Refractory
What this study did
NCT03141203 · University of Birmingham
2015-07-13 – 2021-09-23 · Peripheral T Cell Lymphoma
What this study did
NCT02145403 · University of Michigan Rogel Cancer Center
2014-10 – 2020-10-16 · Hematologic Malignancies, Relapse, Graft-Versus-Host Disease
What this study did
NCT02867618 · Columbia University
2016-10-16 – 2020-06-30 · Hodgkin Disease, Lymphoma, Non-hodgkin
What this study did
NCT02545907 · University College, London
2017-09-14 – 2019-10-21 · Amyloidosis
What this study did
NCT01941316 · Cancer Research and Biostatistics Clinical Trials Consortium
2013-11 – 2019-07-01 · Small Cell Lung Carcinoma, Non Small Cell Lung Carcinoma, Irinotecan Sensitive Cancers
What this study did
NCT02265510 · Incyte Corporation
2014-09-10 – 2019-02-27 · Solid Tumors, Advanced Malignancies, Metastatic Cancer
What this study did
NCT01987232 · Amgen
2013-11-05 – 2017-05-04 · Extensive-Stage Small-Cell Lung Cancer
What this study did
Phase 1 (57)
Multiple Myeloma
NCT06622005 · Roswell Park Cancer Institute
2025-04-10 – 2030-04-10 · Recurrent Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT05651932 · K36 Therapeutics, Inc.
2023-02-22 – 2028-06-30 · Multiple Myeloma, Myeloma, Myeloma Multiple
What this study did
NCT05675449 · Pfizer
2022-12-14 – 2028-02-29 · Multiple Myeloma
What this study did
NCT07082270 · Roswell Park Cancer Institute
2026-04-01 – 2028-02-01 · Recurrent Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT05050097 · Janssen Research & Development, LLC
2021-09-22 – 2027-12-31 · Multiple Myeloma
What this study did
NCT03909412 · Hackensack Meridian Health
2019-10-08 – 2027-08 · Multiple Myeloma
What this study did
NCT03798678 · National Cancer Institute (NCI)
2019-07-08 – 2027-07-16 · Recurrent Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT02332850 · Thomas Martin, MD
2015-01-21 – 2025-12-31 · Multiple Myeloma
What this study did
NCT02199665 · University of Chicago
2014-06-12 – 2025-10-25 · Refractory Multiple Myeloma
What this study did
NCT04813653 · Tel-Aviv Sourasky Medical Center
2021-04-18 – 2025-03-05 · Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
What this study did
NCT03031730 · National Cancer Institute (NCI)
2018-06-14 – 2024-07-24 · Plasmacytoma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT05556616 · Teva Branded Pharmaceutical Products R&D LLC
2023-01-12 – 2024-06-04 · Multiple Myeloma
What this study did
NCT02101944 · National Cancer Institute (NCI)
2014-12-09 – 2024-05-07 · Anemia, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT03605719 · Emory University
2018-10-24 – 2022-10-10 · Recurrent Plasma Cell Myeloma
What this study did
NCT04163107 · Norwegian University of Science and Technology
2020-01-07 – 2021-12-28 · Multiple Myeloma
What this study did
NCT02095834 · M.D. Anderson Cancer Center
2014-04-24 – 2021-01-07 · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT02036502 · Merck Sharp & Dohme LLC
2014-02-14 – 2020-03-19 · Multiple Myeloma
What this study did
NCT01301807 · M.D. Anderson Cancer Center
2011-07-28 – 2019-11-07 · Non-Secretory Plasma Cell Myeloma, Plasmacytosis, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT02335983 · Amgen
2015-04-30 – 2019-10-28 · Multiple Myeloma
What this study did
NCT01372540 · M.D. Anderson Cancer Center
2012-02-24 – 2019-05-16 · Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT02148913 · Corewell Health West
2014-06 – 2018-12 · Multiple Myeloma
What this study did
NCT01549431 · Emory University
2012-01 – 2017-04 · Multiple Myeloma
What this study did
NCT01949532 · Amgen
2014-01 – 2017-01 · Relapsed Multiple Myeloma, End-stage Renal Disease
What this study did
NCT01204164 · Tragara Pharmaceuticals, Inc.
2010-08 – 2016-04 · AML, ALL, Blast Crisis, MDS, Multiple Myeloma
What this study did
NCT00603447 · Amgen
2008-05 – 2016-01 · Relapsed Multiple Myeloma
What this study did
NCT01660750 · Criterium, Inc.
2013-01 – 2015-12 · Multiple Myeloma
What this study did
NCT01537861 · Washington University School of Medicine
2012-06 – 2014-12 · Multiple Myeloma
What this study did
NCT00150462 · Amgen
2005-09 – 2009-10 · Waldenstrom's Macroglobulinemia, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma
What this study did
Other / comorbidity
NCT07715903 · National Cancer Institute (NCI)
2026-11-24 – 2031-12-31 · Colorectal Neoplasms, Neoplasms, Intrahepatic Cholangiocarcinoma, Adrenocortical Carcinoma, Metastasis, Neoplasm
What this study did
NCT06918990 · National Institute of Allergy and Infectious Diseases (NIAID)
2026-05-27 – 2027-06-30 · Kidney Transplant Rejection
What this study did
NCT01959698 · Roswell Park Cancer Institute
2014-04-17 – 2026-12-01 · CD20 Positive, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Stage I Diffuse Large B-Cell Lymphoma, Stage II Diffuse Large B-Cell Lymphoma, Stage III Diffuse Large B-Cell Lymphoma, Stage IV Diffuse Large B-Cell Lymphoma
What this study did
NCT06249282 · City of Hope Medical Center
2024-04-24 – 2026-11-24 · Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
What this study did
NCT02303821 · Amgen
2015-02-16 – 2024-06-28 · Acute Lymphoblastic Leukemia (ALL)
What this study did
NCT02512926 · Stanford University
2016-02-16 – 2023-11-07 · Relapsed Solid Tumors, Refractory Solid Tumors, Relapsed Leukemia, Refractory Leukemia
What this study did
NCT03432741 · Mayo Clinic
2018-03-27 – 2022-10-03 · Breast Adenocarcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Recurrent Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Breast Carcinoma, Refractory Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Nodal Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage IV Breast Cancer AJCC v6 and v7
What this study did
NCT02442648 · E. Steve Woodle
2014-12 – 2021-09 · Transplants and Implants
What this study did
NCT02187133 · University of California, San Francisco
2015-05-05 – 2021-03-31 · Lymphoma, Non-Hodgkin, Lymphoma
What this study did
NCT01729104 · M.D. Anderson Cancer Center
2013-04-25 – 2018-10-03 · Lymphoma
What this study did
NCT02269085 · M.D. Anderson Cancer Center
2015-04-20 – 2018-05-29 · Lymphoma
What this study did
NCT01336920 · University of Nebraska
2011-06-21 – 2018-03-01 · Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Peripheral T-cell Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma
What this study did
NCT02293109 · Mehrdad Abedi, MD
2015-12-17 – 2018-01-11 · Contiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Untreated Adult Acute Lymphoblastic Leukemia
What this study did
NCT02142530 · Massachusetts General Hospital
2014-10 – 2018-01 · Non-Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Peripheral T-cell Lymphoma
What this study did
NCT01991301 · Sheba Medical Center
2014-11 – 2017-11 · Graft-versus-host Disease
What this study did
Phase 4 (4)
Multiple Myeloma
NCT07709884 · The First Affiliated Hospital of Soochow University
2026-07-01 – 2028-12-31 · Newly Diagnosed Multiple Myeloma, T(11;14), Sotoclax, Carfilzomib
What this study did
NCT06409702 · The First Affiliated Hospital of Soochow University
2024-06-12 – 2027-12-31 · Newly Diagnosed, High Risk, MRD, Multiple Myeloma
What this study did
NCT03934684 · Amgen
2019-09-16 – 2025-06-27 · Relapsed Refractory Multiple Myeloma
What this study did
Early phase / not applicable (3)
Multiple Myeloma
NCT06793475 · Institute of Hematology & Blood Diseases Hospital, China
2025-04-09 – 2026-12 · Extramedullary Multiple Myeloma
What this study did
NCT05184595 · Central Hospital, Nancy, France
2022-01-01 – 2024-10-30 · Multiple Myeloma
What this study did
Used as active comparator (9)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (7)
Multiple Myeloma
NCT07555938 · Hoffmann-La Roche
2026-06-23 – 2033-01-31 · Multiple Myeloma
What this study did
NCT06413498 · Kite, A Gilead Company
2024-08-23 – 2031-07 · Multiple Myeloma
What this study did
NCT05675319 · Universitätsklinikum Hamburg-Eppendorf
2023-03-03 – 2025-03-21 · Multiple Myeloma
What this study did
Phase 2 (1)
Phase 1/2 (1)
Multiple Myeloma
NCT07463807 · National Cancer Institute (NCI)
2027-04-12 – 2029-03-31 · Recurrent Multiple Myeloma, Refractory Multiple Myeloma
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (1)
Multiple Myeloma
NCT02628704 · Karyopharm Therapeutics Inc
2015-12 – 2018-06 · Multiple Myeloma
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Multiple Myeloma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Carfilzomib: this drugApprovedSmall moleculeProteasomePartial signal
NCT03158688: Progression-free Survival (PFS) as Assessed by the Independent Review Committee (PA DCO Only) (From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks): Kd - Carfilzomib and Dexamethasone — Participants with PFS events: 68 Participants; Participants who were censored: 86 Participants | KdD - Carfilzomib, Dexamethasone and Daratumumab — Participants with PFS events: 110 Participants; Participants who were censored: 202 Participants
NCT01568866: Progression-free Survival (From randomization until the data cut-off date of 10 November 2014; median follow-up time for PFS was 11.1.and 11.9 months in the bortezomib and carfilzomib arms respectively): Carfilzomib + DEX 18.7 months vs Bortezomib + DEX 9.4 months (95% CI 8.4 to 10.4)
Belantamab MafodotinApprovedAntibody–drug conjugateBCMAPartial signal
NCT04246047: Progression-free Survival (PFS) (Up to approximately 41 months): Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) 36.6 Months vs Daratumumab + Bor + Dex 13.4 Months (95% CI 11.1 to 17.5)
NCT04162210: Progression-Free Survival (PFS) Based on Investigator-Assessed Response as Per International Myeloma Working Group (IMWG) (Up to 27 months): Belantamab Mafodotin 11.2 Months (95% CI 6.4 to 14.5) vs Pomalidomide Plus Dexamethasone 7 Months (95% CI 4.6 to 10.6) missed
BortezomibApprovedSmall moleculeProteasomePartial signal
NCT00722566: Number of Patients With Overall Response (Complete Response + Partial Response) (Over 4 cycles (prior to the addition of dexamethasone)): VELCADE Subcutaneuous 61/145 | VELCADE Intravenous 31/73
NCT00048230: Response rate (CR+PR): 38% bortezomib vs 18% dexamethasone (P<0.001), with CR 6% vs <1%; median time to progression 6.22 vs 3.49 months (HR 0.55, P<0.001); 1-year survival 80% vs 66% (P=0.003), overall survival HR 0.57 (P=0.001).
Ciltacabtagene AutoleucelApprovedCell therapyBCMAPartial signal
NCT04181827: Progression-free survival: median not reached with cilta-cel vs 11.8 months with standard care (hazard ratio 0.26; 95% CI 0.18 to 0.38; P<0.001); 12-month PFS 75.9% vs 48.6% (CARTITUDE-4, N Engl J Med 2023).
DaratumumabApprovedMonoclonal antibodyCD38Partial signal
NCT03901963: Percentage of Participants Who Had Minimal Residual Disease (MRD) Conversion From Baseline to 12 Months After Start of Maintenance Treatment as Determined by Next Generation Sequencing (NGS) (From randomization up to 12 months): Daratumumab + Lenalidomide 50.5% (95% CI 40.3 to 60.7) vs Lenalidomide 18.8% (95% CI 11.7 to 27.8)
NCT02076009: Progression-free survival at the interim analysis: hazard ratio 0.37 (95% CI 0.27 to 0.52; P<0.001); 12-month PFS 83.2% with daratumumab plus lenalidomide/dexamethasone vs 60.1% with lenalidomide/dexamethasone (POLLUX, N Engl J Med 2016).
ElotuzumabApprovedMonoclonal antibodySLAMF7 (CS1/CD319)Partial signal
NCT01335399: Progression-Free Survival (PFS) (From randomization to date of first documented tumor progression or death due to any cause (up to 8 years)): E-Ld Cohort 31.38 Months (95% CI 26.18 to 36.8) vs Ld Cohort 29.47 Months (95% CI 23.49 to 34.3) missed
NCT01239797: Median Progression Free Survival (PFS) (From randomization up to 326 events (up to approximately 38 months)): Lenalidomide + Dexamethasone + Elotuzumab 19.35 Months (95% CI 16.62 to 22.18) vs Lenalidomide + Dexamethasone 14.85 Months (95% CI 12.09 to 17.22)
ElranatamabApprovedMultispecific antibodyBCMA x CD3Weak signalFeatured results are non-efficacy only in this race
Iberdomide (Zenbexus)ApprovedSmall moleculeCereblon E3 ubiquitin-ligasenot yet gradedNo reviewed efficacy summary in this indication
Idecabtagene VicleucelApprovedCell therapyBCMAReliable signal
NCT03651128: PFS 13.3 vs 4.4 mo (HR 0.49 [95% CI 0.38-0.65], p<0.001); ORR 71% vs 42% (p<0.001)
NCT03361748: Overall Response Rate (From first dose to 24 Months): BB2121 74.5% (95% CI 67.1 to 81.8)
IsatuximabApprovedMonoclonal antibodyCD38Partial signal
NCT02990338: Progression Free Survival (PFS) (From the date of randomization to the date of first documentation of progression, or the date of death from any cause, or initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration: 76.7 weeks)): IPd (Isatuximab + Pomalidomide + Dexamethasone) 11.53 months (95% CI 8.936 to 13.897) vs Pd (Pomalidomide + Dexamethasone) 6.47 months (95% CI 4.468 to 8.279)
IxazomibApprovedSmall moleculeProteasomeReliable signal
NCT02312258: Progression Free Survival (PFS) (From randomization until PD or death (up to 52 months)): Ixazomib 17.4 months (95% CI 14.78 to 20.3) vs Placebo 9.4 months (95% CI 8.51 to 11.47)
NCT02181413: Progression Free Survival (PFS) (Randomization up to End of treatment (EOT) (24 months); thereafter followed up every 4 weeks (up to 45 months)): Ixazomib Citrate 26.5 months (95% CI 23.69 to 33.81) vs Placebo 21.3 months (95% CI 17.97 to 24.67)
LenalidomideApprovedSmall moleculeCereblon E3 ubiquitin-ligase, Thalidomide AnalogReliable signal
NCT00424047: Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (From randomization up to cut-off date of 03 August 2005; up to 24 months): Lenalidomide Plus Dexamethasone 52.1 weeks vs Placebo Plus Dexamethasone 20.1 weeks (95% CI 16.6 to 20.7)
NCT00056160: Time to Tumor Progression (TTP) (60 weeks (median Time To Progression of CC-5013/Dex treatment group)): CC-5013/Dex 60.1 Weeks (95% CI 41.1 to 80) vs Placebo/Dex 20.1 Weeks (95% CI 16.1 to 21.1)
LinvoseltamabApprovedMultispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
Melphalan Hydrochloride (Evomela)ApprovedSmall moleculeDNA (guanine N7 position)Weak signal
NCT03159702: Progression-free Survival (PFS) of Participants With Hematological Malignancies Undergoing Treatment. (1 year): MEL/FLU and Total-Body Irradiation (TBI) 17/43
MotixafortideApprovedPeptideCXCR4Partial signal
NCT03246529: Proportion of patients who collected at least 6 x 10^6 CD34+ cells/kg in up to 2 aphereses (central laboratory), randomized Part 2, motixafortide + filgrastim (n=80) vs placebo + filgrastim (n=42): 67.5% vs 9.5%, adjusted difference 56.8%, p < 0.0001 (stratified Cochran-Mantel-Haenszel; APHEXDA US label, section 14). CT.gov posted results for the same randomized groups give 70.0% vs 14.3%, p < 0.0001 (Cochran-Mantel-Haenszel).
NCT02639559: Number of Donors That Mobilize ≥ 2 x 10^6 CD34+ Cells/kg of Recipients Weight After a Single Injection of BL-8040 After no More Than Two Leukapheresis Collections (Arm 1 - Donors Only) (Up to Day 2): Arm 1: Donors 22/24
PlerixaforApprovedSmall moleculeCXCR4Partial signal
NCT00103662: Collection of at least 6 x 10^6 CD34+ cells/kg in 2 or fewer aphereses: plerixafor plus G-CSF 71.6% (106/148) vs placebo plus G-CSF 34.4% (53/154), P<.001 (DiPersio et al., Blood 2009).
PomalidomideApprovedSmall moleculeCereblon (CRBN)Partial signal
NCT01324947: Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria Based on Investigator Assessment (From randomization through the study follow-up phase; up to the data cut-off of 31 July 2014; Maximum time on follow-up was 141.1 weeks.): Pomalidomide 23%
NCT01311687: Progression-free Survival (PFS) - Primary Analysis (From randomization until the data cut-off date of 07 September 2012. Maximum duration of follow-up for PFS assessments was 57 weeks.): Pomalidomide Plus Low-Dose Dexamethasone 15.7 weeks (95% CI 13 to 20.1) vs High-Dose Dexamethasone 8 weeks (95% CI 7 to 9)
SelinexorApprovedSmall moleculeXPO1 (exportin-1)Partial signal
NCT03110562: SVd/Vd Arm: Progression-free Survival (PFS) as Assessed by Independent Review Committee (IRC) (From date of randomization until IRC-confirmed documented PD or death, censored date, whichever occurred first (up to 33 months)): SVd Arm: Selinexor + Bortezomib + Dexamethasone 13.93 Months vs Vd Arm: Bortezomib + Dexamethasone 9.46 Months (95% CI 8.11 to 10.78)
TalquetamabApprovedMultispecific antibodyGPRC5D x CD3not yet gradedNo reviewed efficacy summary in this indication
TeclistamabApprovedMultispecific antibodyBCMA x CD3Partial signal
NCT05083169: Primary endpoint, progression-free survival: teclistamab plus daratumumab was statistically significant and superior to DPd/DVd (J&J, 2025-10-16).
NCT04696809: Phase 2 primary endpoint ORR 76.9% (>=VGPR 76.9%, >=CR 65.4%) in 26 patients at RP2D 1.5 mg/kg; median follow-up 14.32 months
ThalidomideApprovedSmall moleculeCereblon E3 ubiquitin-ligasePartial signalFeatured results are non-efficacy only in this race
Zoledronic Acid (Zometa)ApprovedSmall moleculeFarnesyl pyrophosphate synthase (FPPS)not yet gradedNo reviewed efficacy summary in this indication
PanobinostatUS approval withdrawnSmall moleculeHDACPartial signal
NCT01023308: Progression-free survival (investigator-assessed): median 11.99 months with panobinostat + bortezomib + dexamethasone vs 8.08 months with placebo + bortezomib + dexamethasone; HR 0.63 (95% CI 0.52-0.76), p<0.0001 (Lancet Oncology 2014)
Anitocabtagene AutoleucelPhase 3Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
Arlocabtagene AutoleucelPhase 3Cell therapyGPRC5DWeak signalFeatured results are safety only in this race
AZD0120Phase 3Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
BCD-264Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
CevostamabPhase 3Multispecific antibodyFcRH5 (FcRL5) x CD3not yet gradedNo reviewed efficacy summary in this indication
CT-P44Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
Denosumab (Xgeva)Phase 3Monoclonal antibodyRANKLReliable signal
NCT01345019: Time to First On-study Skeletal Related Event (From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively.): Denosumab 695 days vs Zoledronic Acid 730 days (95% CI 504 to 1014)
Equecabtagene AutoleucelPhase 3Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
EtentamigPhase 3Multispecific antibodyBCMA x CD3Partial signal
NCT06158841: Dual primary endpoints met: objective response rate and progression-free survival vs standard available therapies (PFS HR 0.40, P<0.0001) (AbbVie, 2026-09-03).
F182112Phase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
FelzartamabPhase 3Monoclonal antibodyCD38Partial signal
NCT03952091: Median PFS: 18·9 months felzartamab+Rd vs 10·4 months Rd (hazard ratio 0·62; p=0·0035)
Gamgertamig (CM336)Phase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
HLX15Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
IBI3003Phase 3Multispecific antibodyGPRC5D x BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
InobrodibPhase 3Small moleculeCBP/p300 (bromodomain)not yet gradedNo reviewed efficacy summary in this indication
LumrotatugPhase 3Monoclonal antibodyCD38Weak signal
NCT04818372: CM313 phase 1 dose-escalation/expansion (NCT04818372, anti-CD38 mAb, R/R multiple myeloma + marginal zone lymphoma): grade>=3 TEAEs 15/34 (44.1%), no DLTs; ORR 34.5% among 29 evaluable RRMM patients; median PFS 132 days.
MezigdomidePhase 3Small moleculeCereblon E3 ubiquitin-ligasePartial signal
NCT05552976: Primary endpoint, progression-free survival: statistically significant and clinically meaningful improvement vs carfilzomib and dexamethasone (Bristol Myers Squibb, 2026-03-09).
PlitidepsinPhase 3Small moleculeeEF1A2 (eukaryotic translation elongation factor 1-alpha 2)Partial signal
NCT01102426: Progression Free Survival (PFS) as Per Intention-to-treat (ITT) (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years): Plitidepsin+Dexamethasone 2.6 months (95% CI 1.9 to 3) vs Dexamethasone 1.7 months (95% CI 1.1 to 2)
QL2109Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
QLS32015Phase 3Multispecific antibodyGPRC5D x CD3not yet gradedNo reviewed efficacy summary in this indication
QLS4131Phase 3Multispecific antibodyGPRC5D x BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
RamantamigPhase 3Multispecific antibodyGPRC5D x BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
SanritatugPhase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
SCTC21CPhase 3Biologic (subtype unspecified)CD38not yet gradedNo reviewed efficacy summary in this indication
TorutamigPhase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
TQB2934Phase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
Velinotamig (GR1803)Phase 3Multispecific antibodyBCMA x CD3Weak signalNo reviewed efficacy summary in this indication
VenetoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
Burixafor (TG-0054)Phase 2Small moleculeCXCR4Weak signal
NCT01458288: Number of Patients Achieving the CD34+ Hematopoietic Stem Cell (HSC) Mobilization Target of ≧2.5×1000000 Cells/kg (1 week): TG-0054 (3.14 mg/kg) 7/7 | TG-0054 (3.14 mg/kg)+G-CSF 5/5
NCT01018979: Primary mobilization success: 2/4 patients in the TG-0054 2.24 mg/kg group (MM 1, NHL 1) vs 1/3 patients in the 3.14 mg/kg group (MM 1); no p-value or confidence interval reported.
CemsidomidePhase 2Small moleculeCereblon E3 ubiquitin-ligasenot yet gradedNo reviewed efficacy summary in this indication
Hrain Anti-BCMA CAR-TPhase 2Cell therapyBCMAWeak signalFeatured results are safety only in this race
HRC0202Phase 2Cell therapyBCMAWeak signalFeatured results are safety only in this race
Iopofosine I-131Phase 2Radiopharmaceuticalphospholipid ether (selective lipid raftWeak signal
NCT02278315: The phase 1 dose-escalation and safety study enrolled 31 patients with relapsed or refractory multiple myeloma who had received a median of four prior lines of therapy. It established 31.25 mCi/m2 as the maximum tolerated single dose and identified 20 mCi/m2 administered twice, one week apart, as the highest evaluated fractionated dose regimen.
LMY-920Phase 2Cell therapyBCMA / TACInot yet gradedNo reviewed efficacy summary in this indication
RAPA-201Phase 2Cell therapyRapamycin-resistant autologous T-cell therapyWeak signal
NCT04176380: Overall response rate: 9/14 patients (64%) achieved disease remission (IMWG criteria) - 8 partial responses, 1 stringent complete response.
YKST02Phase 2Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
AZD4045Phase 1/2Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
BCMA CAR-NK (Shenzhen Pregene Biopharma)Phase 1/2Cell therapyBCMAWeak signalNo reviewed efficacy summary in this indication
BCMA-Targeted Prime CAR-T Cells (Chongqing Precision Biotech)Phase 1/2Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
BelantamabPhase 1/2Monoclonal antibodyBCMAnot yet gradedNo reviewed efficacy summary in this indication
TQB3602Phase 1Small moleculeProteasomeWeak signal
NCT04275583: Twenty-five patients with relapsed/refractory multiple myeloma who had relapsed or failed at least 2 lines of therapy were enrolled in the dose-escalation phase. Two patients in the 7.0 mg dose group developed dose-limiting toxicities, giving a maximum tolerated dose of 6.0 mg. Any-grade adverse events occurred in 24 (96.0%) patients and grade >=3 adverse events in 13 (52.0%). Among 22 response-evaluable patients, 63.7% achieved stable disease or better.

Large race: only the 63 furthest-along competitors are listed; 104 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(47 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Carfilzomib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (6)
November 2026 (3)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2026-11 · NCT04973605 · CT.gov ↗
What to watch
Phase 1Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 …Recruiting
Est. primary completion 2026-11-24 · NCT06249282 · CT.gov ↗
What to watch
Phase 1/2Multiple MyelomaActive not recruiting
Est. primary completion 2026-11-30 · NCT03989414 · CT.gov ↗
What to watch
December 2026 (3)
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2026-12-28 · NCT03729804 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2026-12-31 · NCT04883242 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2026-12-31 · NCT01863550 · CT.gov ↗
What to watch
2027 (21)
February 2027 (1)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-02-01 · NCT04268498 · CT.gov ↗
What to watch
April 2027 (3)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-04 · NCT02343042 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-04-01 · NCT06356571 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2027-04-10 · NCT06622005 · CT.gov ↗
What to watch
May 2027 (2)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-05 · NCT04176718 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-05-01 · NCT06627751 · CT.gov ↗
What to watch
June 2027 (4)
Phase 1/2Multiple MyelomaActive not recruiting
Est. primary completion 2027-06 · NCT01297764 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-06 · NCT02899052 · CT.gov ↗
What to watch
Phase 1Kidney Transplant RejectionRecruiting
Est. primary completion 2027-06-30 · NCT06918990 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2027-06-30 · NCT05909826 · CT.gov ↗
What to watch
July 2027 (2)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-07 · NCT07479979 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-07 · NCT03556332 · CT.gov ↗
What to watch
August 2027 (1)
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2027-08 · NCT03909412 · CT.gov ↗
What to watch
September 2027 (1)
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2027-09-01 · NCT04096066 · CT.gov ↗
What to watch
October 2027 (2)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-10 · NCT03004287 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-10-15 · NCT04850599 · CT.gov ↗
What to watch
November 2027 (2)
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2027-11 · NCT02659293 · CT.gov ↗
What to watch
Phase 4Multiple MyelomaRecruiting
Est. primary completion 2027-11-30 · NCT06409702 · CT.gov ↗
What to watch
December 2027 (3)
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2027-12 · NCT06158841 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2027-12-30 · NCT06615479 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2027-12-31 · NCT05651932 · CT.gov ↗
What to watch
2028 (9)
January 2028 (1)
Phase 2POEMS SyndromeRecruiting
Est. primary completion 2028-01 · NCT07652879 · CT.gov ↗
What to watch
February 2028 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-02 · NCT04661137 · CT.gov ↗
What to watch
March 2028 (2)
Phase 2/3Multiple MyelomaRecruiting
Est. primary completion 2028-03 · NCT06879379 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2028-03-25 · NCT05137054 · CT.gov ↗
What to watch
May 2028 (1)
Phase 2Waldenstrom MacroglobulinemiaActive not recruiting
Est. primary completion 2028-05 · NCT04263480 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-07-01 · NCT05789303 · CT.gov ↗
What to watch
August 2028 (1)
Phase 1/2Multiple MyelomaActive not recruiting
Est. primary completion 2028-08 · NCT05434689 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2Multiple MyelomaEnrolling by invitation
Est. primary completion 2028-11-30 · NCT05669989 · CT.gov ↗
What to watch
December 2028 (1)
Phase 4Multiple MyelomaNot yet recruiting
Est. primary completion 2028-12-31 · NCT07709884 · CT.gov ↗
What to watch
2029 (7)
January 2029 (1)
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2029-01-31 · NCT05438043 · CT.gov ↗
What to watch
February 2029 (1)
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2029-02 · NCT07348393 · CT.gov ↗
What to watch
March 2029 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2029-03-01 · NCT05896228 · CT.gov ↗
What to watch
April 2029 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2029-04 · NCT04822337 · CT.gov ↗
What to watch
May 2029 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2029-05-21 · NCT07222761 · CT.gov ↗
What to watch
August 2029 (1)
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2029-08 · NCT03948035 · CT.gov ↗
What to watch
December 2029 (1)
Phase 1Colorectal Neoplasms, Neoplasms, Intrahepatic Cholangiocarcinoma, Adrenocortical Carcinoma, Metastasis, NeoplasmNot yet recruiting
Est. primary completion 2029-12-31 · NCT07715903 · CT.gov ↗
What to watch
2030 (1)
August 2030 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2030-08-30 · NCT07227311 · CT.gov ↗
What to watch
2031 (1)
June 2031 (1)
Phase 2/3Multiple MyelomaRecruiting
Est. primary completion 2031-06-01 · NCT04513639 · CT.gov ↗
What to watch
2032 (1)
November 2032 (1)
Phase 2Plasma Cell LeukemiaRecruiting
Est. primary completion 2032-11-06 · NCT07605416 · CT.gov ↗
What to watch
2035 (1)
December 2035 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2035-12 · NCT06892522 · CT.gov ↗
What to watch

See the full readout calendar ↗